Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

• Main Authors: Yi Long Wu, Nagahiro Saijo, Sumitra Thongprasert, J. C.H. Yang, Baohui Han, Benjamin Margono, Busayamas Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin Ji Yang, Tony S.K. Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka
• Format: Journal
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85009789298&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/56807
• Institution: Chiang Mai University

© 2016 The Authors Objective The Phase III, randomized, open-label IPASS study (NCT00322452) of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) gefitinib versus carboplatin/paclitaxel for Asian patients with advanced non-small-cell lung cancer (NSCLC) showed that inv...